Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
0444 Gel (Metronidazole) for Inflammatory Rosacea
NCT01016782Phase 3Completed
- Sponsor
- Fougera Pharmaceuticals Inc.
- Start
- Jan 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of metronidazole in rosacea (3 arms), sponsored by Fougera Pharmaceuticals Inc. Primary endpoint: Reduction in the number of papules and pustules from Baseline to End of Treatment at 70 days. Started Jan 2008; status: completed.
02
Drugs
metronidazole
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT01016782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01016782.